Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Stargardt Disease: Symptoms, Causes, Treatment and Integrative Support
What Stargardt disease is, how it is diagnosed, which treatments are in clinical trials, and where integrative care fits alongside your retina specialist.
Request a Consultation
Stargardt disease is an inherited eye condition that damages the macula, the small central part of the retina you use to read, drive and recognize faces. It is the most common inherited macular degeneration20, affecting about 1 in 6,500 people, and it usually begins in late childhood or early adulthood2. There is no approved treatment yet, but that may soon change: the U.S. Food and Drug Administration (FDA) is reviewing the first drug for Stargardt disease and has set a decision date of February 12, 20275.
This page covers the symptoms, causes and diagnosis, what helps today, which treatments are in clinical trials, and where integrative care can — and cannot — fit alongside the care of your retina specialist.
Stargardt disease at a glance
| What it is | An inherited macular degeneration that causes central vision loss; side vision is often kept18 |
|---|---|
| How common | About 1 in 6,500 people2 |
| Usual age at onset | Late childhood to early adulthood; some people notice nothing until adulthood1,2 |
| Main gene | ABCA4 (autosomal recessive). Less often ELOVL4 (autosomal dominant)2 |
| Approved treatments | None as of October 20261 |
| Closest to approval | Tinlarebant, a once-daily pill; FDA decision due February 12, 20275 |
| A key step today | Do not take supplements with more than the daily recommended amount of vitamin A1 |
On this page
What is Stargardt disease?
Stargardt disease is a genetic disease of the retina, the light-sensing layer at the back of the eye. It is also called Stargardt macular dystrophy, juvenile macular degeneration, or STGD1 when it is caused by changes in the ABCA4 gene2.
In Stargardt disease, a fatty yellow material called lipofuscin builds up in a layer of support cells beneath the macula, the retinal pigment epithelium. Much of this material is made from by-products of vitamin A, which the retina uses every time it responds to light. Over time the support cells and the light-sensing cells above them stop working and die, leaving patches of wasted tissue (atrophy) in the macula2,18.
Because the damage is concentrated in the macula, Stargardt disease mainly affects central vision. Some side vision is usually kept, so most people can still get around on their own18, although some people lose side vision as well1.
Stargardt disease and age-related macular degeneration (AMD) are different conditions. Both damage the macula, but Stargardt disease is inherited and usually starts in young people, while AMD is linked to aging and usually starts after 50. Research and supplements designed for AMD have not been shown to help Stargardt disease.
Symptoms of Stargardt disease
The most common symptom is a slow loss of central vision in both eyes1. Other symptoms include1,2:
- gray, black or hazy spots in the center of your vision
- trouble reading, seeing fine detail or recognizing faces
- sensitivity to bright light
- taking longer than usual to adjust when you move between bright and dim places
- difficulty getting around in low light
- changes in color vision in some people
Vision loss usually starts in childhood, but some people do not notice changes until adulthood1.
What does someone with Stargardt disease see?
Most people describe a blurry, distorted or missing patch in the middle of whatever they look at directly, while the edges of their vision stay clearer. A word on a page or the face of the person in front of them may be hard to see, even though they can walk around a room without trouble. Many people learn to look slightly to one side of an object so that a healthier part of the retina picks it up; low vision specialists teach this skill.
When to see an eye doctor
Book an eye exam if you or your child has central blur that new glasses do not fix, a new blind spot, or a family history of Stargardt disease or another inherited retinal disease. Early diagnosis does not change the genes, but it allows genetic testing, monitoring, vitamin A guidance and access to clinical trials.
What causes Stargardt disease?
Stargardt disease is caused by changes (variants) in genes that the retina needs to work normally2. It is not caused by anything you did, and it is not contagious.
- ABCA4 (most cases). The ABCA4 gene makes a protein that helps clear vitamin A by-products out of the light-sensing cells. When the protein does not work, those by-products build up and form toxic deposits in the support cells beneath the retina2,18. ABCA4 disease is autosomal recessive: a person must inherit a non-working copy of the gene from each parent. Parents who each carry one copy usually have normal vision, and each of their children has a 1 in 4 chance of having the disease2.
- ELOVL4 (less common). This form is autosomal dominant: one changed copy is enough to cause the disease, so it often appears in several generations of a family2.
The vitamin A link explains two things you will see throughout this page: why doctors warn against extra vitamin A1, and why several of the leading drugs in trials, including tinlarebant and gildeuretinol, aim to change how the eye handles vitamin A5,6.
The disease can look very different from one person to the next, even in people with variants in the same gene18.
How Stargardt disease is diagnosed
An eye doctor can check for Stargardt disease during a dilated eye exam, where yellowish flecks and changes in the macula may be visible1,3. To confirm the diagnosis and track it over time, a retina specialist usually adds1,3:
- Optical coherence tomography (OCT), a scan that shows the layers of the retina in cross-section.
- Fundus photography and fundus autofluorescence (FAF), images that show lipofuscin and areas of atrophy. FAF is the main way clinical trials measure whether the disease is progressing19.
- Electroretinography (ERG), which measures the retina's electrical response to light.
- Color vision testing.
- Genetic testing, which confirms the cause and is usually needed to join a clinical trial7,10.
Through its My Retina Tracker Genetic Testing Program, the Foundation Fighting Blindness lets any U.S. eye care professional order no-cost genetic testing, with genetic counseling, for patients clinically diagnosed with an inherited retinal disease14.
We ask every patient to keep a retina specialist or inherited retinal disease clinic at the center of their care, and we work from their test results.
Stargardt disease treatment today
There is no FDA-approved treatment for Stargardt disease yet1. These steps are what eye specialists currently recommend:
- Avoid extra vitamin A. Do not take dietary supplements with more than the daily recommended amount of vitamin A1. On supplement labels, look for retinol, retinyl palmitate, retinyl acetate, beta-carotene, fish-liver oils such as cod liver oil, and liver-based products. The phase 3 NORTHSTAR trial, for example, excludes anyone who has taken vitamin A, beta-carotene or liver-based products in the previous 30 days7. Ask your retina specialist before starting any eye vitamin.
- Protect your eyes from bright light. Wear a hat and sunglasses outdoors1.
- Do not smoke or vape3.
- Use low vision aids and rehabilitation. Low vision aids and rehabilitation (training) programs can help you make the most of your remaining vision1. Examples include magnifiers, high-contrast settings and screen readers.
- Keep regular check-ups with a retina specialist, and keep copies of your OCT, FAF and genetic test reports.
- Ask about clinical trials. For many people, a trial is the only way to receive a treatment that might slow the disease today.
New treatments for Stargardt disease in clinical trials
Most treatments in development aim to slow the disease rather than restore lost vision. Trials usually measure success by how fast the areas of atrophy grow on FAF images. In a large natural history study, these areas grew by about 0.76 square millimeters a year on average, and how fast they grew depended on how large they already were19. Slower growth is expected to preserve vision for longer, but no drug has yet been shown to improve vision in a controlled trial.
| Treatment | How it works | Stage (October 2026) | What the results show so far |
|---|---|---|---|
| Tinlarebant (Belite Bio) | A once-daily pill that lowers the protein that carries vitamin A from the liver to the eye5 | New drug application accepted with priority review; FDA decision due February 12, 20275 | DRAGON phase 3 trial: 104 people aged 12 to 20, treated for 24 months. Lesions grew 35.7% more slowly than with placebo. Generally well tolerated; the most common eye side effects were a yellow tint to vision and slower adjustment to the dark, mostly mild4 |
| Gildeuretinol (ALK-001, Alkeus Pharmaceuticals) | A modified form of vitamin A designed to form fewer toxic by-products without slowing the retina's normal use of vitamin A6,18 | Phase 3 NORTHSTAR trial recruiting about 230 people aged 8 to 45; main results expected after October 20297 | TEASE-1 trial: 50 adults aged 18 to 60 with atrophy, 24 months. Lesions grew 21.6% more slowly than in an untreated comparison group that included natural-history patients, and 14.9% more slowly than with placebo alone. No reports of night blindness or delayed dark adaptation6,21 |
| MCO-010 (Nanoscope Therapeutics) | A one-time gene therapy injected into the eye that makes surviving retinal cells sensitive to light; it works whichever gene is affected9 | Phase 3 trial (STARGAZE, about 60 people) planned but not yet started as of October 20269,22 | STARLIGHT phase 2 trial: 6 people with severe vision loss, no control group. Average gain of 5.5 letters on the eye chart after 48 weeks, 9 letters with a low vision aid. No serious side effects reported9 |
| Metformin (National Eye Institute) | A common diabetes drug being tested in people with ABCA4 disease | Phase 1/2 trial, 55 people enrolled; main results expected in 202810 | No results yet |
| Emixustat (Kubota Vision) | A pill that slows the retina's vitamin A cycle | Phase 3 SeaSTAR trial did not meet its main goal in 202211 | Did not slow lesion growth compared with placebo |
| Gene therapy and cell therapy | Replacing the faulty ABCA4 gene, or replacing lost retinal cells with cells grown from stem cells | Laboratory research and early safety trials18 | Not yet proven in people. ABCA4 is a very large gene, which makes it harder to deliver with standard gene therapy tools18 |
If tinlarebant is approved, the FDA will decide which patients it is approved for. Its main trial studied adolescents4.
How to find a clinical trial
Start with genetic testing, because most trials enroll people by gene7,10; through the Foundation Fighting Blindness, a U.S. eye care professional can order it at no cost14. Then search ClinicalTrials.gov for "Stargardt", ask your retina specialist, and check the Foundation Fighting Blindness website. Tell any trial team about every supplement, herb and integrative treatment you use, because some can affect whether you qualify or how results are read.
A warning about clinics selling stem cell treatments
In 2017, doctors reported three women with macular degeneration who were left with severe vision loss after a clinic in Florida injected cells processed from their own fat into both eyes12,13. Be cautious if a clinic asks you to pay for an experimental treatment, offers to treat both eyes on the same day, or points to a ClinicalTrials.gov listing as proof that a treatment works. A listing only means a study was registered13.
Living with Stargardt disease
- Low vision rehabilitation. A low vision specialist can match magnifiers, lighting, phone and computer settings, and reading techniques to your vision. Low vision aids and training help people make the most of their remaining vision1.
- School and work. Students may qualify for classroom accommodations, and adults may be able to request workplace accommodations. Ask your eye doctor for a letter describing your vision.
- Driving. Whether you can drive depends on your state's vision standards. Your eye doctor can test you against them.
- Family. Because Stargardt disease is inherited, brothers, sisters and children may want genetic counseling14.
- Support. Patient groups such as the Foundation Fighting Blindness connect families and share trial news.
Where integrative care fits
Netra Eye Institute offers integrative eye care: acupuncture, nutrition and lifestyle guidance, Traditional Chinese Medicine and Ayurveda. For Stargardt disease we offer it alongside care from a retina specialist, never instead of it. Here is what research does and does not show.
| Approach | What has been studied in Stargardt disease | What it found |
|---|---|---|
| Saffron | One randomized, placebo-controlled trial in 31 people with ABCA4 Stargardt disease15 | Saffron was well tolerated. Retinal function and vision did not improve over six months; the authors called for longer trials to see whether it slows decline |
| Lutein | Six months of lutein supplements in people with ABCA4-related disease16 | Raised the protective pigment in the macula in 63% of eyes; central vision did not change |
| Acupuncture | No randomized trial in Stargardt disease has been published. One small study without a comparison group enrolled 33 people with various macular diseases17 | Not enough evidence to say whether acupuncture changes the course of Stargardt disease |
| Eye vitamins made for AMD (AREDS-type formulas) | Studied in age-related macular degeneration, not Stargardt disease | Check with your retina specialist first and check the label for vitamin A |
What working with us looks like
- We review every supplement, herbal formula and Ayurvedic or TCM product you take for vitamin A, beta-carotene and liver-based ingredients, including retinol, retinyl palmitate, retinyl acetate and fish-liver oils7.
- We ask for your latest OCT, FAF and genetic results so we work from the same information as your retina specialist.
- If you are in, or hoping to join, a clinical trial, the trial comes first. We adjust or pause anything the trial team asks us to.
- Netra Restoration Therapy (NRT) is our individualized program that combines ocular acupuncture, nutrition and lifestyle guidance, and botanical and Ayurvedic principles. NRT has not been tested in a controlled trial in Stargardt disease. It is not a cure, and we do not promise that it will improve or preserve vision.
For more on our approach, read Holistic support for Stargardt disease. Clinicians can find the mechanism-level rationale in Stargardt disease: mechanisms, function and NRT support.
Outlook
Stargardt disease usually progresses slowly, over years rather than months, and the pace varies a great deal from person to person18,19. Most people lose some or all of their central vision over time3. Some side vision is usually kept18, though not by everyone1. For the first time, a treatment designed to slow the disease is under FDA review5. Another drug, gildeuretinol, is in a phase 3 trial, and a phase 3 trial of the gene therapy MCO-010 is planned7,9.
Frequently asked questions
Is there a cure for Stargardt disease?
No. There is no cure and no approved treatment yet1. The first drug for Stargardt disease, tinlarebant, is under FDA review with a decision due February 12, 20275. It is designed to slow the disease, not reverse it4.
Will I go blind from Stargardt disease?
Most people lose some or all of their central vision3, but some side vision is usually kept, so most people can still get around18. How much vision is lost, and how fast, varies widely18.
At what age does Stargardt disease start?
Symptoms usually begin in late childhood to early adulthood. Some people do not notice changes until adulthood1.
Is Stargardt disease hereditary?
Yes. Most cases are autosomal recessive and caused by the ABCA4 gene, so both parents carry a copy. A less common dominant form is caused by the ELOVL4 gene2.
What is the newest treatment for Stargardt disease?
Tinlarebant is the furthest along. In its phase 3 trial in adolescents, lesions grew 35.7% more slowly than with placebo over 24 months4, and the FDA is reviewing it with a decision due February 12, 20275. Gildeuretinol is in a phase 3 trial, and a phase 3 trial of MCO-010 is planned7,9.
Should people with Stargardt disease avoid vitamin A?
They should not take supplements with more than the daily recommended amount of vitamin A1. Ask your retina specialist about anything beyond that.
Can stem cells cure Stargardt disease?
No stem cell treatment has been proven to work for Stargardt disease, and research is at an early stage18. Unregulated clinics have caused severe vision loss12,13.
Can acupuncture or Ayurveda treat Stargardt disease?
There is no clinical trial evidence that acupuncture, Ayurveda or any herbal treatment slows Stargardt disease17. Netra offers these as supportive care alongside your retina specialist, without any promise about vision.
How do I join a Stargardt clinical trial?
Get genetic testing first, because most trials select people by gene7,10; through the Foundation Fighting Blindness, a U.S. eye care professional can order it at no cost14. Then search ClinicalTrials.gov and ask your retina specialist.
Book an integrative consultation
Please bring your most recent retina reports and a list of every supplement you take. Call (732) 503-9999 or use our contact form.
Request a consultationSources
- National Eye Institute. Stargardt disease. Updated 4 December 2024.
- MedlinePlus Genetics. Stargardt macular degeneration.
- Cleveland Clinic. Stargardt disease.
- Belite Bio. Phase 3 DRAGON trial results for tinlarebant. 1 December 2025.
- Foundation Fighting Blindness. FDA accepts new drug application, prioritizes review for potential Stargardt treatment. 14 August 2026.
- Alkeus Pharmaceuticals. TEASE-1 results published in JAMA Ophthalmology. 3 September 2026.
- Alkeus Pharmaceuticals. First patient dosed in phase 3 NORTHSTAR study, 8 June 2026; and ClinicalTrials.gov NCT07419334.
- American Academy of Ophthalmology. Gildeuretinol for Stargardt disease. January 2025.
- Nanoscope Therapeutics. STARLIGHT phase 2 publication. 14 August 2025.
- ClinicalTrials.gov. Oral metformin for treatment of ABCA4 retinopathy, NCT04545736.
- Kubota Vision. Phase 3 SeaSTAR study of emixustat in Stargardt disease. 3 October 2022. Trial record: NCT03772665.
- Kuriyan AE, et al. Vision loss after intravitreal injection of autologous "stem cells" for AMD. N Engl J Med. 2017.
- Foundation Fighting Blindness. Unregulated stem cell therapy causes severe vision loss for three Florida women.
- Foundation Fighting Blindness. No-cost genetic testing.
- Piccardi M, et al. Antioxidant saffron and central retinal function in ABCA4-related Stargardt macular dystrophy. Nutrients. 2019.
- Aleman TS, et al. Macular pigment and lutein supplementation in ABCA4-associated retinal degenerations. Invest Ophthalmol Vis Sci. 2007.
- ClinicalTrials.gov. Efficacy of acupuncture in macular diseases, NCT02255981. Single group, 33 participants, completed 2016.
- Zaydon YA, Tsang SH. The ABCs of Stargardt disease: the latest advances in precision medicine. Cell Biosci. 2024.
- Strauss RW, et al. Progression of Stargardt disease as determined by fundus autofluorescence over a 12-month period: ProgStar Report No. 11. JAMA Ophthalmol. 2019.
- Foundation Fighting Blindness. Stargardt disease.
- Kay CN, et al. TEASE-1 randomized clinical trial of gildeuretinol in Stargardt disease. JAMA Ophthalmol. 2026;144(10):944–952. PMID 42690655.
- Nanoscope Therapeutics. Company update on Eyecelerator 2026 and AAO 2026 participation, including plans for a phase 3 Stargardt trial. 6 October 2026.